The percentages of IL17-, IL9-, and IL4-producing cells in CD4+T cells were significantly higher in MS patients than in HCs (p<0.01 for all), and the percentages of IFNγ-, IL17-, IL9-, and IL4-producing cells in CD8+T cells were also significantly higher in MS patients than in HCs (p<0.05, p<0.01, p<0.01, and p<0.05, respectively) (Fig 3). This evidence concerns the gene IL9 and myeloid sarcoma.